Natera Reports 38.8% Revenue Growth, Exceeds 1M Tests, Raises 2026 Guidance
NTRA sits 58% above its 52-week low of $131.811 on elevated volume (2.0× avg).
Summary
Natera reported robust first-quarter 2026 results, with revenue surging 38.8% year-over-year to $696.6 million, driven by higher test volumes and improved pricing. The company achieved a significant operational milestone by processing over one million tests in the quarter. Despite an increased net loss of $85.1 million, the strong top-line growth and operational scale are positive indicators. Crucially, Natera raised its full-year 2026 revenue guidance, signaling confidence in continued strong performance. This news provides a material update on the company's financial health and future outlook, making it highly actionable for traders.
At the time of this announcement, NTRA was trading at $208.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.2B. The 52-week trading range was $131.81 to $256.36. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.